WebDec 6, 2024 · Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in... WebFeb 10, 2024 · This is part of Negma Group Investment Ltd.’s EUR 15 million Capital Commitment 1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate ...
Funding Program between Oxurion and Negma Ends
WebApr 11, 2024 · Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 [email protected] Michael Dillen Chief Business Officer Tel: +32 479 783583 WebNegma Group is aangegaan. Oxurion ontving op 12 april 2024 een transparantiekennisgeving van Atlas Special Opportunities LLC. waaruit blijkt dat het op 11 april 2024 26,728,439 aandelen van de toen uitstaande 632,659,186 aandelen bezat en dus boven de drempel (3%) kwam van stemrechtverlenende effecten. Zie bijlage 1 Over … hello kitty y2k widget
Funding Program between Oxurion and Negma Ends
WebOxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide. WebJan 25, 2024 · The initial funding program totaled EUR 30 million in two parts, and pursuant to the amendment, Oxurion and Negma have mutually agreed to wind-down the funding program after the completion of the first part, which reduces the total funding under the funding program to EUR 15 million. Negma has waived the liquidity requirement and … WebJan 25, 2024 · Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in... hello kitty y2k wallpaper pc